AbCellera Biologics Inc.

AbCellera Biologics Inc. is a biotechnology firm that engages in researching and developing human antibodies. It was founded in 2012 with its headquarters in Vancouver, Canada. It operates mainly in Canada. AbCellera studies natural immune systems to find antibodies. Once found, they are decoded and analysed for drug development aimed at overall health improvement. The search for systems is done via the screening of different species. Trianni operates as AbCellera's complete functional human antibody repertoire. Study of the different antibodies along with diverse species has led to breakthroughs in biotechnology and immune profiling. In 2018, AbCellera celebrated the opening of its new research facility and corporate headquarters. As of 31 December 2020, the company has 103 discovery programs that are either completed, in progress, or under contract. It has entered into a discovery partnership agreement with Eli Lilly and Company. AbCellera uses other biotechnology techniques and equipment to improve its platform, such as Celium, its antibody visualisation and exploration software. The company's customised single-cell assays allow it to convert antibody responses into raw data for further analysis. From that data, it can use repertoire sequencing to nominate solutions for diseases. AbCellera trades on the NASDAQ under the ticker ABCL. Follow ABCL shares and stay up to date on its value changes here on eToro.